Systemics & biologics (psoriasis/eczema)
also: methotrexate · ciclosporin · adalimumab · secukinumab · dupilumab · biologics
Overview
Systemic therapy for severe psoriasis and atopic eczema when topicals/phototherapy fail. Biologics target specific cytokines; screen for infection/TB first.
Mechanism
Conventional: methotrexate (antifolate, antiproliferative/immunosuppressive), ciclosporin (calcineurin inhibitor), apremilast (PDE4 inhibitor). Biologics neutralise the cytokines driving disease: TNF-α (adalimumab/etanercept/infliximab), IL-17 (secukinumab/ixekizumab), IL-23 (guselkumab/risankizumab), IL-12/23 (ustekinumab); IL-4/13 (dupilumab — eczema).
Indications
- Moderate–severe plaque psoriasis (+ psoriatic arthritis)
- Severe atopic eczema (dupilumab, JAK inhibitors)
The agents
WEEKLY + folic acid
Cross-references the rheumatology/cross-cutting card; pneumonitis, myelosuppression, hepatotoxicity.
Rapid; nephrotoxic, hypertension, gum hyperplasia — short-term.
SC/IV
TB reactivation — screen + treat latent TB first.
SC
IL-17 can flare IBD / cause candidiasis.
SC
Severe atopic eczema; conjunctivitis.
Adverse effects
Screen (IGRA/CXR) before starting.
Cautions & contraindications
Teratogen/abortifacient.
Interactions
- Methotrexate + trimethoprim/NSAIDs → marrow toxicity
- Live vaccines contraindicated
Monitoring & kinetics
Pre-biologic: TB + hepatitis B/C + HIV screen,Methotrexate: FBC/U&E/LFTs,Ciclosporin: renal function + BP
MTX weekly oral/SC; biologics SC/IV at intervals.
Source: NICE CG153 — Psoriasis · BNF — Drugs affecting the immune response